References:
1. Zhu, R., et al., Current progress in cancer treatment using
nanomaterials. Frontiers in Oncology, 2022. 12 .
2. Cheng, Z., et al., Nanomaterials for cancer therapy: Current
progress and perspectives. Journal of hematology & oncology, 2021.14 (1): p. 1-27.
3. Sun, G., et al., Role of small molecule targeted compounds in
cancer: progress, opportunities, and challenges. Frontiers in cell and
developmental biology, 2021. 9 : p. 694363.
4. Zhong, L., et al., Small molecules in targeted cancer therapy:
Advances, challenges, and future perspectives. Signal transduction and
targeted therapy, 2021. 6 (1): p. 201.
5. Tan, S., et al., Exosomal miRNAs in tumor microenvironment.Journal of Experimental & Clinical Cancer Research, 2020. 39 :
p. 1-15.
6. Zhong, S., et al., Targeting tumor microenvironment by
small-molecule inhibitors. Translational oncology, 2020.13 (1): p. 57-69.
7. Lucero, R., et al., Glioma-derived miRNA-containing
extracellular vesicles induce angiogenesis by reprogramming brain
endothelial cells. Cell reports, 2020. 30 (7): p. 2065-2074.
e4.
8. Varricchi, G., et al., Innate effector cells in angiogenesis
and lymphangiogenesis. Current opinion in immunology, 2018.53 : p. 152-160.
9. Petrova, V., et al., The hypoxic tumour microenvironment.Oncogenesis, 2018. 7 (1): p. 10.
10. Zeltz, C., et al. Cancer-associated fibroblasts in
desmoplastic tumors: emerging role of integrins . in Seminars in
cancer biology . 2020. Elsevier.
11. Ma, L., et al., Tumor cell biodiversity drives
microenvironmental reprogramming in liver cancer. Cancer cell, 2019.36 (4): p. 418-430. e6.
12. Zhang, X., et al., Inhibiting PI3 kinase-γ in both myeloid and
plasma cells remodels the suppressive tumor microenvironment in
desmoplastic tumors. Journal of Controlled Release, 2019. 309 :
p. 173-180.
13. Clément-Colmou, K., et al., Influence of radiotherapy
fractionation schedule on the tumor vascular microenvironment in
prostate and lung cancer models. Cancers, 2020. 12 (1): p. 121.
14. Armignacco, R., et al., The adipose stem cell as a novel
metabolic actor in adrenocortical carcinoma progression: Evidence from
an in vitro tumor microenvironment crosstalk model. Cancers, 2019.11 (12): p. 1931.
15. Lei, X., et al., Immune cells within the tumor
microenvironment: Biological functions and roles in cancer
immunotherapy. Cancer letters, 2020. 470 : p. 126-133.
16. Zhang, H., et al., CAF secreted miR-522 suppresses ferroptosis
and promotes acquired chemo-resistance in gastric cancer. Molecular
cancer, 2020. 19 : p. 1-17.
17. De Palma, M., D. Biziato, and T.V. Petrova, Microenvironmental
regulation of tumour angiogenesis. Nature Reviews Cancer, 2017.17 (8): p. 457-474.
18. Moriwaki, K. and M. Asahi, Augmented TME O-GlcNAcylation
Promotes Tumor Proliferation through the Inhibition of p38 MAPKEffect of
O-GlcNAcylation in the TME. Molecular Cancer Research, 2017.15 (9): p. 1287-1298.
19. Khalaf, K., et al., Aspects of the tumor microenvironment
involved in immune resistance and drug resistance. Frontiers in
immunology, 2021. 12 : p. 656364.
20. Whiteside, T.L. Exosome and mesenchymal stem cell cross-talk
in the tumor microenvironment . in Seminars in immunology . 2018.
Elsevier.
21. Xie, F., et al., Extracellular vesicles in cancer immune
microenvironment and cancer immunotherapy. Advanced science, 2019.6 (24): p. 1901779.
22. Daassi, D., K.M. Mahoney, and G.J. Freeman, The importance of
exosomal PDL1 in tumour immune evasion. Nature Reviews Immunology,
2020. 20 (4): p. 209-215.
23. Jarosz-Biej, M., et al., Tumor microenvironment as a “game
changer” in cancer radiotherapy. International journal of molecular
sciences, 2019. 20 (13): p. 3212.
24. Peng, J., et al., Intratumoral fate of functional
nanoparticles in response to microenvironment factor: Implications on
cancer diagnosis and therapy. Advanced Drug Delivery Reviews, 2019.143 : p. 37-67.
25. Maacha, S., et al., Extracellular vesicles-mediated
intercellular communication: roles in the tumor microenvironment and
anti-cancer drug resistance. Molecular cancer, 2019. 18 : p.
1-16.
26. Sullivan, R., et al., The emerging roles of extracellular
vesicles as communication vehicles within the tumor microenvironment and
beyond. Frontiers in Endocrinology, 2017. 8 : p. 194.
27. Van Niel, G., G. d’Angelo, and G. Raposo, Shedding light on
the cell biology of extracellular vesicles. Nature reviews Molecular
cell biology, 2018. 19 (4): p. 213-228.
28. Minciacchi, V.R., M.R. Freeman, and D. Di Vizio. Extracellular
vesicles in cancer: exosomes, microvesicles and the emerging role of
large oncosomes . in Seminars in cell & developmental biology .
2015. Elsevier.
29. Maas, S.L., X.O. Breakefield, and A.M. Weaver, Extracellular
vesicles: unique intercellular delivery vehicles. Trends in cell
biology, 2017. 27 (3): p. 172-188.
30. Bebelman, M.P., et al., Biogenesis and function of
extracellular vesicles in cancer. Pharmacology & therapeutics, 2018.188 : p. 1-11.
31. Tovar-Camargo, O.A., S. Toden, and A. Goel, Exosomal microRNA
biomarkers: emerging frontiers in colorectal and other human cancers.Expert review of molecular diagnostics, 2016. 16 (5): p.
553-567.
32. Higginbotham, J.N., et al., Amphiregulin exosomes increase
cancer cell invasion. Current Biology, 2011. 21 (9): p.
779-786.
33. Rak, J. and A. Guha, Extracellular vesicles–vehicles that
spread cancer genes. Bioessays, 2012. 34 (6): p. 489-497.
34. Naito, Y., et al., How cancer cells dictate their
microenvironment: present roles of extracellular vesicles. Cellular and
Molecular Life Sciences, 2017. 74 : p. 697-713.
35. Fu, H., et al., The emerging roles of exosomes in
tumor–stroma interaction. Journal of cancer research and clinical
oncology, 2016. 142 : p. 1897-1907.
36. Santos, P. and F. Almeida, Role of exosomal miRNAs and the
tumor microenvironment in drug resistance. Cells, 2020. 9 (6):
p. 1450.
37. Xu, R., et al., Extracellular vesicles in
cancer—implications for future improvements in cancer care. Nature
reviews Clinical oncology, 2018. 15 (10): p. 617-638.
38. Li, I. and B.Y. Nabet, Exosomes in the tumor microenvironment
as mediators of cancer therapy resistance. Molecular cancer, 2019.18 : p. 1-10.
39. Gangoda, L., et al., Extracellular vesicles including exosomes
are mediators of signal transduction: are they protective or
pathogenic? Proteomics, 2015. 15 (2-3): p. 260-271.
40. Steinbichler, T.B., et al., Therapy resistance mediated by
exosomes. Molecular cancer, 2019. 18 (1): p. 1-11.
41. Mashouri, L., et al., Exosomes: composition, biogenesis, and
mechanisms in cancer metastasis and drug resistance. Molecular cancer,
2019. 18 : p. 1-14.
42. Milman, N., L. Ginini, and Z. Gil, Exosomes and their role in
tumorigenesis and anticancer drug resistance. Drug Resistance Updates,
2019. 45 : p. 1-12.
43. Anfossi, S., et al., MicroRNAs, regulatory messengers inside
and outside cancer cells. Exosomes, Stem Cells and MicroRNA: Aging,
Cancer and Age Related Disorders, 2018: p. 87-108.
44. Fattore, L., et al., Reprogramming miRNAs global expression
orchestrates development of drug resistance in BRAF mutated melanoma.Cell Death & Differentiation, 2019. 26 (7): p. 1267-1282.
45. Malhotra, A., et al., Stabilization of miRNAs in esophageal
cancer contributes to radioresistance and limits efficacy of therapy.Biochimie, 2019. 156 : p. 148-157.
46. Yan, W., et al., Cancer-cell-secreted exosomal miR-105
promotes tumour growth through the MYC-dependent metabolic reprogramming
of stromal cells. Nature cell biology, 2018. 20 (5): p.
597-609.
47. Zhou, C.-F., et al., Cervical squamous cell carcinoma-secreted
exosomal miR-221-3p promotes lymphangiogenesis and lymphatic metastasis
by targeting VASH1. Oncogene, 2019. 38 (8): p. 1256-1268.
48. Cai, L., et al., Epstein–Barr virus-encoded microRNA BART1
induces tumour metastasis by regulating PTEN-dependent pathways in
nasopharyngeal carcinoma. Nature communications, 2015. 6 (1):
p. 7353.
49. Tian, R., et al., Differential expression of miR16 in
glioblastoma and glioblastoma stem cells: their correlation with
proliferation, differentiation, metastasis and prognosis. Oncogene,
2017. 36 (42): p. 5861-5873.
50. Uddin, M.N., M. Li, and X. Wang, Identification of
Transcriptional Markers and microRNA–mRNA Regulatory Networks in Colon
Cancer by Integrative Analysis of mRNA and microRNA Expression Profiles
in Colon Tumor Stroma. Cells, 2019. 8 (9): p. 1054.
51. Slack, F.J. and A.M. Chinnaiyan, The role of non-coding RNAs
in oncology. Cell, 2019. 179 (5): p. 1033-1055.
52. Kanchan, R.K., et al., microRNAs orchestrate pathophysiology
of breast cancer brain metastasis: advances in therapy. Molecular
cancer, 2020. 19 (1): p. 1-16.
53. Conti, I., et al., miRNAs as influencers of cell–cell
communication in tumor microenvironment. Cells, 2020. 9 (1): p.
220.
54. Cheng, W.C., et al., RAB27B‐activated secretion of stem‐like
tumor exosomes delivers the biomarker microRNA‐146a‐5p, which promotes
tumorigenesis and associates with an immunosuppressive tumor
microenvironment in colorectal cancer. International Journal of Cancer,
2019. 145 (8): p. 2209-2224.
55. Patel, H., et al., Modulating secreted components of tumor
microenvironment: A masterstroke in tumor therapeutics. Cancer Biology
& Therapy, 2018. 19 (1): p. 3-12.
56. Wang, M., et al., Emerging function and clinical values of
exosomal microRNAs in cancer. Molecular therapy-Nucleic acids, 2019.16 : p. 791-804.
57. Sun, Z., et al., Effect of exosomal miRNA on cancer biology
and clinical applications. Molecular cancer, 2018. 17 : p.
1-19.
58. Pontecorvi, G., et al., Tumor-derived extracellular vesicles
and microRNAs: Functional roles, diagnostic, prognostic and therapeutic
options. Cytokine & Growth Factor Reviews, 2020. 51 : p.
75-83.
59. Bach, D.H., et al., The role of exosomes and miRNAs in
drug‐resistance of cancer cells. International journal of cancer, 2017.141 (2): p. 220-230.
60. Seo, H.A., et al., Microrna-based combinatorial cancer
therapy: Effects of micrornas on the efficacy of anti-cancer therapies.Cells, 2019. 9 (1): p. 29.
61. Sharma, A., Chemoresistance in cancer cells: exosomes as
potential regulators of therapeutic tumor heterogeneity. Nanomedicine,
2017. 12 (17): p. 2137-2148.
62. Au Yeung, C.L., et al., Exosomal transfer of stroma-derived
miR21 confers paclitaxel resistance in ovarian cancer cells through
targeting APAF1. Nature communications, 2016. 7 (1): p. 11150.
63. Chen, Y., et al., Tumor-associated macrophages: an accomplice
in solid tumor progression. Journal of biomedical science, 2019.26 (1): p. 1-13.
64. Netea-Maier, R.T., J.W. Smit, and M.G. Netea, Metabolic
changes in tumor cells and tumor-associated macrophages: a mutual
relationship. Cancer letters, 2018. 413 : p. 102-109.
65. Sawa-Wejksza, K. and M. Kandefer-Szerszeń, Tumor-associated
macrophages as target for antitumor therapy. Archivum immunologiae et
therapiae experimentalis, 2018. 66 : p. 97-111.
66. Park, J.E., et al., Hypoxia-induced tumor exosomes promote
M2-like macrophage polarization of infiltrating myeloid cells and
microRNA-mediated metabolic shift. Oncogene, 2019. 38 (26): p.
5158-5173.
67. Cooks, T., et al., Mutant p53 cancers reprogram macrophages to
tumor supporting macrophages via exosomal miR-1246. Nature
communications, 2018. 9 (1): p. 771.
68. Hsieh, C.-H., S.-K. Tai, and M.-H. Yang, Snail-overexpressing
cancer cells promote M2-like polarization of tumor-associated
macrophages by delivering MiR-21-abundant exosomes. Neoplasia, 2018.20 (8): p. 775-788.
69. Lin, F., et al., Bladder cancer cell‑secreted exosomal miR‑21
activates the PI3K/AKT pathway in macrophages to promote cancer
progression. International journal of oncology, 2020. 56 (1):
p. 151-164.
70. Chen, X., et al., Exosomes derived from hypoxic epithelial
ovarian cancer deliver microRNA-940 to induce macrophage M2
polarization. Oncology Reports, 2017. 38 (1): p. 522-528.
71. Chen, X., et al., Exosomes derived from hypoxic epithelial
ovarian cancer cells deliver microRNAs to macrophages and elicit a
tumor-promoted phenotype. Cancer letters, 2018. 435 : p. 80-91.
72. Nieto, M.A., Epithelial plasticity: a common theme in
embryonic and cancer cells. Science, 2013. 342 (6159): p.
1234850.
73. Gavert, N. and A. Ben-Ze’ev, Epithelial–mesenchymal
transition and the invasive potential of tumors. Trends in molecular
medicine, 2008. 14 (5): p. 199-209.
74. Du, B. and J.S. Shim, Targeting epithelial–mesenchymal
transition (EMT) to overcome drug resistance in cancer. Molecules,
2016. 21 (7): p. 965.
75. Bigagli, E., et al., Transcriptomic characterization,
chemosensitivity and regulatory effects of exosomes in spontaneous
EMT/MET transitions of breast cancer cells. Cancer Genomics &
Proteomics, 2019. 16 (3): p. 163-173.
76. Hardin, H., et al., Thyroid cancer stem-like cell exosomes:
regulation of EMT via transfer of lncRNAs. Laboratory Investigation,
2018. 98 (9): p. 1133-1142.
77. Xiao, D., et al., Melanoma cell–derived exosomes promote
epithelial–mesenchymal transition in primary melanocytes through
paracrine/autocrine signaling in the tumor microenvironment. Cancer
letters, 2016. 376 (2): p. 318-327.
78. Mizushima, N. and M. Komatsu, Autophagy: renovation of cells
and tissues. Cell, 2011. 147 (4): p. 728-741.
79. Huang, F., B.-R. Wang, and Y.-G. Wang, Role of autophagy in
tumorigenesis, metastasis, targeted therapy and drug resistance of
hepatocellular carcinoma. World journal of gastroenterology, 2018.24 (41): p. 4643.
80. Folkerts, H., et al., The multifaceted role of autophagy in
cancer and the microenvironment. Medicinal research reviews, 2019.39 (2): p. 517-560.
81. Janji, B., G. Berchem, and S. Chouaib, Targeting autophagy in
the tumor microenvironment: new challenges and opportunities for
regulating tumor immunity. Frontiers in Immunology, 2018. 9 :
p. 887.
82. Gewirtz, D.A., Cytoprotective and nonprotective autophagy in
cancer therapy . 2013, Taylor & Francis. p. 1263-1265.
83. Dutta, S., et al., Interactions between exosomes from breast
cancer cells and primary mammary epithelial cells leads to generation of
reactive oxygen species which induce DNA damage response, stabilization
of p53 and autophagy in epithelial cells. PloS one, 2014.9 (5): p. e97580.
84. Liu, D.X., et al., Exosomes derived from HBV‑associated liver
cancer promote chemoresistance by upregulating chaperone‑mediated
autophagy. Oncology Letters, 2019. 17 (1): p. 323-331.
85. Qu, Y., et al., Exosomes derived from miR‐181‐5p‐modified
adipose‐derived mesenchymal stem cells prevent liver fibrosis via
autophagy activation. Journal of cellular and molecular medicine, 2017.21 (10): p. 2491-2502.
86. Chen, J., et al., Micro RNA‐30a ameliorates hepatic fibrosis
by inhibiting Beclin1‐mediated autophagy. Journal of Cellular and
Molecular Medicine, 2017. 21 (12): p. 3679-3692.
87. Yuwen, D., et al., Prognostic role of circulating exosomal
miR-425-3p for the response of NSCLC to platinum-based chemotherapy.Cancer Epidemiology, Biomarkers & Prevention, 2019. 28 (1): p.
163-173.
88. Pathania, A.S. and K.B. Challagundla, Exosomal long non-coding
RNAs: emerging players in the tumor microenvironment. Molecular
Therapy-Nucleic Acids, 2021. 23 : p. 1371-1383.
89. Zhang, Z., et al., Exosomal transfer of long non-coding RNA
SBF2-AS1 enhances chemoresistance to temozolomide in glioblastoma.Journal of Experimental & Clinical Cancer Research, 2019.38 (1): p. 1-16.
90. Masoud, G.N. and W. Li, HIF-1α pathway: role, regulation and
intervention for cancer therapy. Acta Pharmaceutica Sinica B, 2015.5 (5): p. 378-389.
91. Takahashi, K., et al., Modulation of hypoxia-signaling
pathways by extracellular linc-RoR. Journal of cell science, 2014.127 (7): p. 1585-1594.
92. Xue, M., et al., Hypoxic exosomes facilitate bladder tumor
growth and development through transferring long non-coding RNA-UCA1.Molecular cancer, 2017. 16 : p. 1-13.
93. Sun, K., et al., Paradoxical roles of autophagy in different
stages of tumorigenesis: protector for normal or cancer cells. Cell &
bioscience, 2013. 3 (1): p. 1-8.
94. Ding, L., et al., A novel stromal lncRNA signature reprograms
fibroblasts to promote the growth of oral squamous cell carcinoma via
LncRNA-CAF/interleukin-33. Carcinogenesis, 2018. 39 (3): p.
397-406.
95. Warburg, O., F. Wind, and E. Negelein, The metabolism of
tumors in the body. The Journal of general physiology, 1927.8 (6): p. 519.
96. Liberti, M.V. and J.W. Locasale, The Warburg effect: how does
it benefit cancer cells? Trends in biochemical sciences, 2016.41 (3): p. 211-218.
97. Papa, S., P.M. Choy, and C. Bubici, The ERK and JNK pathways
in the regulation of metabolic reprogramming. Oncogene, 2019.38 (13): p. 2223-2240.
98. Baghban, R., et al., Tumor microenvironment complexity and
therapeutic implications at a glance. Cell Communication and Signaling,
2020. 18 : p. 1-19.
99. Liu, T., et al., Cancer-associated fibroblasts build and
secure the tumor microenvironment. Frontiers in cell and developmental
biology, 2019. 7 : p. 60.
100. Walker, C., E. Mojares, and A. del Río Hernández, Role of
extracellular matrix in development and cancer progression.International journal of molecular sciences, 2018. 19 (10): p.
3028.
101. Lu, P., V.M. Weaver, and Z. Werb, The extracellular matrix: a
dynamic niche in cancer progression. Journal of cell biology, 2012.196 (4): p. 395-406.
102. Senthebane, D.A., et al., The role of tumor microenvironment
in chemoresistance: to survive, keep your enemies closer. International
journal of molecular sciences, 2017. 18 (7): p. 1586.
103. Page-McCaw, A., A.J. Ewald, and Z. Werb, Matrix
metalloproteinases and the regulation of tissue remodelling. Nature
reviews Molecular cell biology, 2007. 8 (3): p. 221-233.
104. Cox, T.R. and J.T. Erler, Remodeling and homeostasis of the
extracellular matrix: implications for fibrotic diseases and cancer.Disease models & mechanisms, 2011. 4 (2): p. 165-178.
105. Theocharis, A.D., et al., Extracellular matrix structure.Advanced drug delivery reviews, 2016. 97 : p. 4-27.
106. Wei, R., et al., Cellular and extracellular components in
tumor microenvironment and their application in early diagnosis of
cancers. Analytical Cellular Pathology, 2020. 2020 .
107. Clause, K.C. and T.H. Barker, Extracellular matrix signaling
in morphogenesis and repair. Current opinion in biotechnology, 2013.24 (5): p. 830-833.
108. Tan, T.-T. and L.M. Coussens, Humoral immunity, inflammation
and cancer. Current opinion in immunology, 2007. 19 (2): p.
209-216.
109. Liu, H., H. Zhao, and Y. Sun. Tumor microenvironment and
cellular senescence: Understanding therapeutic resistance and harnessing
strategies . in Seminars in Cancer Biology . 2022. Elsevier.
110. Schuster, R., et al., The inflammatory speech of
fibroblasts. Immunological reviews, 2021. 302 (1): p. 126-146.
111. Wu, P., et al., Adaptive mechanisms of tumor therapy
resistance driven by tumor microenvironment. Frontiers in cell and
developmental biology, 2021. 9 : p. 641469.
112. Ni, Y., et al., The role of tumor-stroma interactions in drug
resistance within tumor microenvironment. Frontiers in Cell and
Developmental Biology, 2021. 9 : p. 637675.
113. Morin, P.J., Drug resistance and the microenvironment: nature
and nurture. Drug Resistance Updates, 2003. 6 (4): p. 169-172.
114. Chen, Y., et al., Therapeutic remodeling of the tumor
microenvironment enhances nanoparticle delivery. Advanced Science,
2019. 6 (5): p. 1802070.
115. Jo, Y., et al., Chemoresistance of cancer cells: requirements
of tumor microenvironment-mimicking in vitro models in anti-cancer drug
development. Theranostics, 2018. 8 (19): p. 5259.
116. Xu, S., et al., The role of collagen in cancer: from bench to
bedside. Journal of translational medicine, 2019. 17 : p. 1-22.
117. Natarajan, S., et al., Collagen remodeling in the hypoxic
tumor-mesothelial niche promotes ovarian cancer metastasis. Cancer
research, 2019. 79 (9): p. 2271-2284.
118. Naito, Y., et al., Micro RNA‐143 regulates collagen type III
expression in stromal fibroblasts of scirrhous type gastric cancer.Cancer science, 2014. 105 (2): p. 228-235.
119. Mu, W., S. Rana, and M. Zöller, Host matrix modulation by
tumor exosomes promotes motility and invasiveness. Neoplasia, 2013.15 (8): p. 875-IN4.
120. Mathot, P., et al., DNA methylation signal has a major role
in the response of human breast cancer cells to the microenvironment.Oncogenesis, 2017. 6 (10): p. e390-e390.
121. Roodhart, J.M., et al., Mesenchymal stem cells induce
resistance to chemotherapy through the release of platinum-induced fatty
acids. Cancer cell, 2011. 20 (3): p. 370-383.
122. Han, Z., et al., Mesenchymal stem cells contribute to the
chemoresistance of hepatocellular carcinoma cells in inflammatory
environment by inducing autophagy. Cell & bioscience, 2014.4 (1): p. 1-11.
123. Ji, R., et al., Exosomes derived from human mesenchymal stem
cells confer drug resistance in gastric cancer. Cell cycle, 2015.14 (15): p. 2473-2483.
124. Xu, H., et al., Tumor‑derived mesenchymal‑stem‑cell‑secreted
IL‑6 enhances resistance to cisplatin via the STAT3 pathway in breast
cancer. Oncology Letters, 2018. 15 (6): p. 9142-9150.
125. Lu, M., et al., Notoginsenoside R1 counteracts mesenchymal
stem cell-evoked oncogenesis and doxorubicin resistance in osteosarcoma
cells by blocking IL-6 secretion-induced JAK2/STAT3 signaling.Investigational New Drugs, 2021. 39 : p. 416-425.
126. Raghavan, S., et al., Carcinoma-associated mesenchymal stem
cells promote chemoresistance in ovarian cancer stem cells via PDGF
signaling. Cancers, 2020. 12 (8): p. 2063.
127. Wang, S., et al., The CXCR4 antagonist, AMD3100, reverses
mesenchymal stem cell-mediated drug resistance in relapsed/refractory
acute lymphoblastic leukemia. OncoTargets and therapy, 2020.13 : p. 6583.
128. Ridge, S.M., F.J. Sullivan, and S.A. Glynn, Mesenchymal stem
cells: key players in cancer progression. Molecular cancer, 2017.16 (1): p. 1-10.
129. Wang, J., et al., Cell adhesion-mediated mitochondria
transfer contributes to mesenchymal stem cell-induced chemoresistance on
T cell acute lymphoblastic leukemia cells. Journal of Hematology &
Oncology, 2018. 11 (1): p. 1-13.
130. Shi, Y., et al., Tumour-associated mesenchymal stem/stromal
cells: emerging therapeutic targets. Nature reviews Drug discovery,
2017. 16 (1): p. 35-52.
131. Scherzed, A., et al., BMSC enhance the survival of paclitaxel
treated squamous cell carcinoma cells in vitro. Cancer Biology &
Therapy, 2011. 11 (3): p. 349-357.
132. Luo, J., et al., Infiltrating bone marrow mesenchymal stem
cells increase prostate cancer stem cell population and metastatic
ability via secreting cytokines to suppress androgen receptor
signaling. Oncogene, 2014. 33 (21): p. 2768-2778.
133. Adamo, A., et al., Role of mesenchymal stromal cell-derived
extracellular vesicles in tumour microenvironment. Biochimica et
Biophysica Acta (BBA)-Reviews on Cancer, 2019. 1871 (1): p.
192-198.
134. Wu, Q., et al., Unraveling adipocytes and Cancer links: is
there a role for senescence? Frontiers in cell and developmental
biology, 2020. 8 : p. 282.
135. Cao, Y., Adipocyte and lipid metabolism in cancer drug
resistance. The Journal of clinical investigation, 2019.129 (8): p. 3006-3017.
136. Nieman, K.M., et al., Adipose tissue and adipocytes support
tumorigenesis and metastasis. Biochimica et Biophysica Acta
(BBA)-Molecular and Cell Biology of Lipids, 2013. 1831 (10): p.
1533-1541.
137. Deng, T., et al., Obesity, inflammation, and cancer. Annual
Review of Pathology: Mechanisms of Disease, 2016. 11 : p.
421-449.
138. Elaraby, E., et al., Natural Killer Cell Dysfunction in Obese
Patients with Breast Cancer: A Review of a Triad and Its Implications.Journal of Immunology Research, 2021. 2021 .
139. Duong, M.N., et al., The fat and the bad: Mature adipocytes,
key actors in tumor progression and resistance. Oncotarget, 2017.8 (34): p. 57622.
140. Yu, W., et al., Adipocytes secreted leptin is a pro-tumor
factor for survival of multiple myeloma under chemotherapy. Oncotarget,
2016. 7 (52): p. 86075.
141. Satoh, M., et al., Modulation of resistance to anticancer
drugs by inhibition of metallothionein synthesis. Cancer research,
1994. 54 (20): p. 5255-5257.
142. Choi, J., Y.J. Cha, and J.S. Koo, Adipocyte biology in breast
cancer: From silent bystander to active facilitator. Progress in lipid
research, 2018. 69 : p. 11-20.
143. Iyengar, P., et al., Adipocyte-derived collagen VI affects
early mammary tumor progression in vivo, demonstrating a critical
interaction in the tumor/stroma microenvironment. The Journal of
clinical investigation, 2005. 115 (5): p. 1163-1176.
144. Sherman-Baust, C.A., et al., Remodeling of the extracellular
matrix through overexpression of collagen VI contributes to cisplatin
resistance in ovarian cancer cells. Cancer cell, 2003. 3 (4):
p. 377-386.
145. Pérez de Heredia, F., I.S. Wood, and P. Trayhurn, Hypoxia
stimulates lactate release and modulates monocarboxylate transporter
(MCT1, MCT2, and MCT4) expression in human adipocytes. Pflügers
Archiv-European Journal of Physiology, 2010. 459 : p. 509-518.
146. Yang, E., et al., Exosome-mediated metabolic reprogramming:
the emerging role in tumor microenvironment remodeling and its influence
on cancer progression. Signal transduction and targeted therapy, 2020.5 (1): p. 242.
147. Sheng, X., et al., Adipocytes sequester and metabolize the
chemotherapeutic daunorubicin. Molecular Cancer Research, 2017.15 (12): p. 1704-1713.
148. Arneth, B., Tumor microenvironment. Medicina, 2019.56 (1): p. 15.
149. Hulikova, A. and P. Swietach, Rapid CO2 permeation across
biological membranes: implications for CO2 venting from tissue. The
FASEB Journal, 2014. 28 (7): p. 2762-2774.
150. Vaupel, P. and A. Mayer, Hypoxia in tumors:
pathogenesis-related classification, characterization of hypoxia
subtypes, and associated biological and clinical implications. Oxygen
transport to tissue XXXVI, 2014: p. 19-24.
151. Rohani, N., et al., Acidification of tumor at stromal
boundaries drives transcriptome alterations associated with aggressive
phenotypes. Cancer research, 2019. 79 (8): p. 1952-1966.
152. Peppicelli, S., et al., The acidic microenvironment as a
possible niche of dormant tumor cells. Cellular and molecular life
sciences, 2017. 74 : p. 2761-2771.
153. Hanahan, D. and R.A. Weinberg, Hallmarks of cancer: the next
generation. cell, 2011. 144 (5): p. 646-674.
154. Siska, P.J., et al., The immunological Warburg effect: Can a
metabolic‐tumor‐stroma score (MeTS) guide cancer immunotherapy?Immunological reviews, 2020. 295 (1): p. 187-202.
155. Apicella, M., et al., Increased lactate secretion by cancer
cells sustains non-cell-autonomous adaptive resistance to MET and EGFR
targeted therapies. Cell metabolism, 2018. 28 (6): p. 848-865.
e6.
156. Yoshida, G.J., Metabolic reprogramming: the emerging concept
and associated therapeutic strategies. Journal of experimental &
clinical cancer research, 2015. 34 : p. 1-10.
157. Martinez-Outschoorn, U.E., et al., Cancer metabolism: a
therapeutic perspective. Nature reviews Clinical oncology, 2017.14 (1): p. 11-31.
158. Gupta, S., A. Roy, and B.S. Dwarakanath, Metabolic
cooperation and competition in the tumor microenvironment: implications
for therapy. Frontiers in oncology, 2017. 7 : p. 68.
159. Wang, Q., et al., Role of tumor microenvironment in cancer
progression and therapeutic strategy. Cancer Medicine, 2023.
160. Libutti, S.K., L. Tamarkin, and N. Nilubol, Targeting the
invincible barrier for drug delivery in solid cancers: interstitial
fluid pressure. Oncotarget, 2018. 9 (87): p. 35723.
161. Yu, T., et al., High interstitial fluid pressure promotes
tumor progression through inducing lymphatic metastasis-related protein
expressions in oral squamous cell carcinoma. Clinical and Translational
Oncology, 2014. 16 : p. 539-547.
162. Haider, T., et al., Recent advances in tumor microenvironment
associated therapeutic strategies and evaluation models. Materials
Science and Engineering: C, 2020. 116 : p. 111229.
163. Trédan, O., et al., Drug resistance and the solid tumor
microenvironment. Journal of the National Cancer Institute, 2007.99 (19): p. 1441-1454.
164. Chen, F., et al., New horizons in tumor microenvironment
biology: challenges and opportunities. BMC medicine, 2015.13 (1): p. 1-14.
165. Wang, S., et al., Tumor microenvironment in chemoresistance,
metastasis and immunotherapy of pancreatic cancer. American journal of
cancer research, 2020. 10 (7): p. 1937.
166. Romano, A., et al., PMN-MDSC and arginase are increased in
myeloma and may contribute to resistance to therapy. Expert review of
molecular diagnostics, 2018. 18 (7): p. 675-683.
167. Calcinotto, A., et al., IL-23 secreted by myeloid cells
drives castration-resistant prostate cancer. Nature, 2018.559 (7714): p. 363-369.
168. Dzobo, K., D.A. Senthebane, and C. Dandara, The tumor
microenvironment in tumorigenesis and therapy resistance revisited.Cancers, 2023. 15 (2): p. 376.
169. Maimela, N.R., S. Liu, and Y. Zhang, Fates of CD8+ T cells in
tumor microenvironment. Computational and structural biotechnology
journal, 2019. 17 : p. 1-13.
170. Bamias, A., et al., Correlation of NK T-like CD3+ CD56+ cells
and CD4+ CD25+ (hi) regulatory T cells with VEGF and TNFα in ascites
from advanced ovarian cancer: Association with platinum resistance and
prognosis in patients receiving first-line, platinum-based
chemotherapy. Gynecologic oncology, 2008. 108 (2): p. 421-427.
171. Long, Y., et al., Dysregulation of glutamate transport
enhances treg function that promotes VEGF blockade resistance in
glioblastoma. Cancer research, 2020. 80 (3): p. 499-509.
172. Imbert, C., et al., Resistance of melanoma to immune
checkpoint inhibitors is overcome by targeting the sphingosine
kinase-1. Nature communications, 2020. 11 (1): p. 437.
173. Li, C., et al., Foxp3 overexpression decreases sensitivity to
chemotherapy in mouse Lewis lung cancer cells. Molecular medicine
reports, 2012. 6 (5): p. 977-982.
174. Wang, D., et al., Colorectal cancer cell-derived CCL20
recruits regulatory T cells to promote chemoresistance via
FOXO1/CEBPB/NF-κB signaling. Journal for immunotherapy of cancer, 2019.7 (1): p. 1-15.
175. Schuler, P.J., et al., Effects of Adjuvant Chemoradiotherapy
on the Frequency and Function of Regulatory T Cells in Patients with
Head and Neck CancerCD4+ CD39+ Treg and CRT. Clinical cancer research,
2013. 19 (23): p. 6585-6596.
176. Liu, X.-D., et al., Resistance to Antiangiogenic Therapy Is
Associated with an Immunosuppressive Tumor Microenvironment in
Metastatic Renal Cell CarcinomaAntiangiogenic Therapy Increases PD-L1
Expression. Cancer immunology research, 2015. 3 (9): p.
1017-1029.
177. Aspord, C., et al., Breast cancer instructs dendritic cells
to prime interleukin 13–secreting CD4+ T cells that facilitate tumor
development. The Journal of experimental medicine, 2007.204 (5): p. 1037-1047.
178. Vicari, A.P., C. Caux, and G. Trinchieri. Tumour escape from
immune surveillance through dendritic cell inactivation . inSeminars in cancer biology . 2002. Elsevier.
179. Incio, J., et al., Obesity-induced inflammation and
desmoplasia promote pancreatic cancer progression and resistance to
chemotherapy. Cancer discovery, 2016. 6 (8): p. 852-869.
180. Shaul, M.E. and Z.G. Fridlender, Tumour-associated
neutrophils in patients with cancer. Nature reviews Clinical oncology,
2019. 16 (10): p. 601-620.
181. Bui, T.M., L.K. Yalom, and R. Sumagin, Tumor-associated
neutrophils: orchestrating cancer pathobiology and therapeutic
resistance. Expert opinion on therapeutic targets, 2021.25 (7): p. 573-583.
182. Chong, A.S.-F., et al., Diverse
multidrug-resistance-modification agents inhibit cytolytic activity of
natural killer cells. Cancer Immunology, Immunotherapy, 1993.36 : p. 133-139.
183. Savas, B., et al., P-glycoprotein-mediated multidrug
resistance and cytotoxic effector cells. Nat Immun, 1992.11 (4): p. 177-92.
184. Takahashi, M., et al., Role of P-glycoprotein in human
natural killer-like cell line-mediated cytotoxicity. Experimental Cell
Research, 1999. 253 (2): p. 396-402.
185. Sugimura, K., et al., High infiltration of tumor‐associated
macrophages is associated with a poor response to chemotherapy and poor
prognosis of patients undergoing neoadjuvant chemotherapy for esophageal
cancer. Journal of surgical oncology, 2015. 111 (6): p.
752-759.
186. Li, X., et al., Harnessing tumor-associated macrophages as
aids for cancer immunotherapy. Molecular Cancer, 2019. 18 (1):
p. 1-16.
187. Liu, Y. and X. Cao, The origin and function of
tumor-associated macrophages. Cellular & molecular immunology, 2015.12 (1): p. 1-4.
188. Moradi-Chaleshtori, M., et al., In vitro and in vivo
evaluation of anti-tumoral effect of M1 phenotype induction in
macrophages by miR-130 and miR-33 containing exosomes. Cancer
Immunology, Immunotherapy, 2021. 70 : p. 1323-1339.
189. Huang, W.-C., et al., Cisplatin resistant lung cancer cells
promoted M2 polarization of tumor-associated macrophages via the
Src/CD155/MIF functional pathway. Journal of Experimental & Clinical
Cancer Research, 2019. 38 (1): p. 1-17.
190. Liu, H., et al., Jagged1 promotes aromatase inhibitor
resistance by modulating tumor-associated macrophage differentiation in
breast cancer patients. Breast Cancer Research and Treatment, 2017.166 : p. 95-107.
191. Yu, S., et al., Activated HIF1α of tumor cells promotes
chemoresistance development via recruiting GDF15-producing
tumor-associated macrophages in gastric cancer. Cancer Immunology,
Immunotherapy, 2020. 69 : p. 1973-1987.
192. Amit, M. and Z. Gil, Macrophages increase the resistance of
pancreatic adenocarcinoma cells to gemcitabine by upregulating cytidine
deaminase. Oncoimmunology, 2013. 2 (12): p. e27231.
193. Weizman, N., et al., Macrophages mediate gemcitabine
resistance of pancreatic adenocarcinoma by upregulating cytidine
deaminase. Oncogene, 2014. 33 (29): p. 3812-3819.
194. Binenbaum, Y., et al., Transfer of miRNA in
Macrophage-Derived Exosomes Induces Drug Resistance in Pancreatic
AdenocarcinomaExosomes Induce Gemcitabine Resistance in Pancreatic
Cancer. Cancer research, 2018. 78 (18): p. 5287-5299.
195. Xian, G., et al., Simvastatin attenuates macrophage-mediated
gemcitabine resistance of pancreatic ductal adenocarcinoma by regulating
the TGF-β1/Gfi-1 axis. Cancer letters, 2017. 385 : p. 65-74.
196. Ireland, L., et al., Chemoresistance in Pancreatic Cancer Is
Driven by Stroma-Derived Insulin-Like Growth FactorsStroma-Derived IGFs
Enhance Chemoresistance in PDAC. Cancer research, 2016.76 (23): p. 6851-6863.
197. Kuwada, K., et al., The epithelial-to-mesenchymal transition
induced by tumor-associated macrophages confers chemoresistance in
peritoneally disseminated pancreatic cancer. Journal of Experimental &
Clinical Cancer Research, 2018. 37 : p. 1-10.
198. Huang, H., et al., Reciprocal Network between Cancer
Stem-Like Cells and Macrophages Facilitates the Progression and Androgen
Deprivation Therapy Resistance of Prostate CancerCSC-Mø Facilitates the
Progression and ADT Resistance of PCa. Clinical cancer research, 2018.24 (18): p. 4612-4626.
199. Torgovnick, A. and B. Schumacher, DNA repair mechanisms in
cancer development and therapy. Frontiers in genetics, 2015.6 : p. 157.
200. Wang, M., S. Chen, and D. Ao, Targeting DNA repair pathway in
cancer: Mechanisms and clinical application. MedComm, 2021.2 (4): p. 654-691.
201. Kiwerska, K. and K. Szyfter, DNA repair in cancer initiation,
progression, and therapy—a double-edged sword. Journal of applied
genetics, 2019. 60 (3-4): p. 329-334.
202. Goldstein, M. and M.B. Kastan, The DNA damage response:
implications for tumor responses to radiation and chemotherapy. Annual
review of medicine, 2015. 66 : p. 129-143.
203. Abbotts, R., N. Thompson, and S. Madhusudan, DNA repair in
cancer: emerging targets for personalized therapy. Cancer management
and research, 2014: p. 77-92.
204. Huang, R. and P.-K. Zhou, DNA damage repair: Historical
perspectives, mechanistic pathways and clinical translation for targeted
cancer therapy. Signal Transduction and Targeted Therapy, 2021.6 (1): p. 254.
205. Blasiak, J., Single-strand annealing in cancer.International Journal of Molecular Sciences, 2021. 22 (4): p.
2167.
206. Jackson, S.P. and J. Bartek, The DNA-damage response in human
biology and disease. Nature, 2009. 461 (7267): p. 1071-1078.
207. Jurkovicova, D., et al., DNA Damage Response in Cancer
Therapy and Resistance: Challenges and Opportunities. International
Journal of Molecular Sciences, 2022. 23 (23): p. 14672.
208. Czerninski, R., et al., Promoter hypermethylation of mismatch
repair genes, hMLH1 and hMSH2 in oral squamous cell carcinoma. Oral
diseases, 2009. 15 (3): p. 206-213.
209. Guan, H., et al., Hypermethylation of the DNA mismatch repair
gene hMLH1 and its association with lymph node metastasis and T1799A
BRAF mutation in patients with papillary thyroid cancer. Cancer, 2008.113 (2): p. 247-255.
210. Wang, Y.-C., et al., Inactivation of hMLH1 and hMSH2 by
promoter methylation in primary non-small cell lung tumors and matched
sputum samples. The Journal of clinical investigation, 2003.111 (6): p. 887-895.
211. Lee, M.-N., et al., Epigenetic inactivation of the
chromosomal stability control genes BRCA1, BRCA2, and XRCC5 in
non–small cell lung cancer. Clinical cancer research, 2007.13 (3): p. 832-838.
212. Liu, K., et al., Promoter hypermethylation: an important
epigenetic mechanism for hMLH1 gene inactivation in head and neck
squamous cell carcinoma. Otolaryngology-Head and Neck Surgery, 2002.126 (5): p. 548-553.
213. Fleisher, A.S., et al., Hypermethylation of the hMLH1 gene
promoter is associated with microsatellite instability in early human
gastric neoplasia. Oncogene, 2001. 20 (3): p. 329-335.
214. Bernal, C., et al., DNA methylation profile in diffuse type
gastric cancer: evidence for hypermethylation of the BRCA1 promoter
region in early-onset gastric carcinogenesis. Biological research,
2008. 41 (3): p. 303-315.
215. Seedhouse, C., E. Das-Gupta, and N. Russell, Methylation of
the hMLH1 promoter and its association with microsatellite instability
in acute myeloid leukemia. Leukemia, 2003. 17 (1): p. 83-88.
216. Zhang, L. and X. Long, Association of BRCA1 promoter
methylation with sporadic breast cancers: Evidence from 40 studies.Scientific reports, 2015. 5 (1): p. 17869.
217. Gras, E., et al., Loss of heterozygosity on chromosome
13q12–q14, BRCA‐2 mutations and lack of BRCA‐2 promoter
hypermethylation in sporadic epithelial ovarian tumors. Cancer, 2001.92 (4): p. 787-795.
218. Yu, J., et al., A novel set of DNA methylation markers in
urine sediments for sensitive/specific detection of bladder cancer.Clinical cancer research, 2007. 13 (24): p. 7296-7304.
219. Fojo, T., Cancer, DNA repair mechanisms, and resistance to
chemotherapy . 2001, Oxford University Press. p. 1434-1436.
220. Phi, L.T.H., et al., Cancer stem cells (CSCs) in drug
resistance and their therapeutic implications in cancer treatment. Stem
cells international, 2018. 2018 .
221. Papaccio, F., et al., Concise review: cancer cells, cancer
stem cells, and mesenchymal stem cells: influence in cancer
development. Stem cells translational medicine, 2017. 6 (12):
p. 2115-2125.
222. Aramini, B., et al., Dissecting tumor growth: the role of
cancer stem cells in drug resistance and recurrence. Cancers, 2022.14 (4): p. 976.
223. Pattabiraman, D.R. and R.A. Weinberg, Tackling the cancer
stem cells—what challenges do they pose? Nature reviews Drug
discovery, 2014. 13 (7): p. 497-512.
224. Yang, Z.-J. and R.J. Wechsler-Reya, Hit’em where they live:
targeting the cancer stem cell niche. Cancer cell, 2007.11 (1): p. 3-5.
225. Gaggianesi, M., et al., Messing up the cancer stem cell
chemoresistance mechanisms supported by tumor microenvironment.Frontiers in Oncology, 2021: p. 2847.
226. Li, Y., et al., Drug resistance and Cancer stem cells. Cell
Communication and Signaling, 2021. 19 (1): p. 1-11.
227. Prieto-Vila, M., et al., Drug resistance driven by cancer
stem cells and their niche. International journal of molecular
sciences, 2017. 18 (12): p. 2574.
228. Barbato, L., et al., Cancer stem cells and targeting
strategies. Cells, 2019. 8 (8): p. 926.
229. Liang, L. and A.M. Kaufmann, The Significance of Cancer Stem
Cells and Epithelial–Mesenchymal Transition in Metastasis and
Anti-Cancer Therapy. International Journal of Molecular Sciences, 2023.24 (3): p. 2555.
230. Agliano, A., A. Calvo, and C. Box. The challenge of targeting
cancer stem cells to halt metastasis . in Seminars in Cancer
Biology . 2017. Elsevier.
231. Knoll, S., S. Emmrich, and B.M. Pützer, The E2F1-miRNA cancer
progression network. MicroRNA Cancer Regulation: Advanced Concepts,
Bioinformatics and Systems Biology Tools, 2013: p. 135-147.
232. Dar, A.A., et al., miRNA-205 suppresses melanoma cell
proliferation and induces senescence via regulation of E2F1 protein.Journal of Biological Chemistry, 2011. 286 (19): p. 16606-16614.
233. Gregory, P.A., et al., The miR-200 family and miR-205
regulate epithelial to mesenchymal transition by targeting ZEB1 and
SIP1. Nature cell biology, 2008. 10 (5): p. 593-601.
234. Godlewski, J., et al., Targeting of the Bmi-1 oncogene/stem
cell renewal factor by microRNA-128 inhibits glioma proliferation and
self-renewal. Cancer research, 2008. 68 (22): p. 9125-9130.
235. Deng, J., et al., Long non-coding RNA HOTAIR regulates the
proliferation, self-renewal capacity, tumor formation and migration of
the cancer stem-like cell (CSC) subpopulation enriched from breast
cancer cells. PLoS One, 2017. 12 (1): p. e0170860.
236. O’Brien, C.A., et al., ID1 and ID3 regulate the self-renewal
capacity of human colon cancer-initiating cells through p21. Cancer
cell, 2012. 21 (6): p. 777-792.
237. Nahand, J.S., et al., microRNAs: new prognostic, diagnostic,
and therapeutic biomarkers in cervical cancer. Journal of cellular
physiology, 2019. 234 (10): p. 17064-17099.
238. Naeli, P., et al., Circular RNAs and gastrointestinal
cancers: epigenetic regulators with a prognostic and therapeutic role.Critical reviews in oncology/hematology, 2020. 145 : p. 102854.
239. Yan, H. and P. Bu, Non-coding RNAs in cancer stem cells.Cancer letters, 2018. 421 : p. 121-126.
240. Davis, B.N. and A. Hata, Regulation of MicroRNA Biogenesis: A
miRiad of mechanisms. Cell Communication and Signaling, 2009.7 : p. 1-22.